Izotropic (IZO) AI Stock Analysis

• Market Cap: C$17.04M
• Dividend Yield: N/A
• Average Volume (3M): 61.89K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.37
• Revenue Growth: N/A
• EPS Growth: 60.83%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 72
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.03
• Shares Outstanding: 56,796,345
• 10 Day Avg. Volume: 47,973
• 30 Day Avg. Volume: 61,886
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -55.60
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Izotropic faces significant financial challenges with weak financials and unattractive valuation. While technical indicators show some positive momentum, financial instability remains the primary concern. Corporate events suggest potential future improvements, but current financial weaknesses dominate the score.

Izotropic Business Overview & Revenue Model

Company Description

Izotropic Corporation (IZO) is a medical technology company specializing in the development and commercialization of advanced imaging solutions for the early detection and diagnosis of breast cancer. The company's flagship product is the Izoview, a dedicated breast CT imaging system designed to provide high-resolution, 3D images of breast tissue, offering improved diagnostic accuracy and patient comfort compared to traditional mammography. Izotropic operates within the medical imaging and healthcare sectors, focusing on innovative technologies to enhance breast cancer screening and diagnostics.

How the Company Makes Money

Izotropic makes money primarily through the development, sale, and potential licensing of its Izoview breast CT imaging systems to healthcare providers, hospitals, and diagnostic centers. The company may generate revenue from direct sales of the imaging systems, as well as through service and maintenance contracts and potential software upgrades. Additionally, Izotropic could explore partnerships with medical institutions and research organizations for collaborative studies and clinical trials, which may also contribute to its revenue streams. Key factors contributing to its earnings include the adoption rate of its imaging technology within the healthcare sector, regulatory approvals, and market expansion efforts.

Izotropic Financial Statement Overview

Summary

Izotropic's financial health is precarious, marked by zero revenue, high losses, negative equity, and unsustainable cash flow. These factors indicate significant financial instability.

Income Statement

Izotropic has consistently reported zero revenue across all periods, indicating a lack of sales traction. The company is incurring high losses, with negative gross profit and net income margins, as evident in the TTM. This suggests significant challenges in managing costs and achieving profitability.

Balance Sheet

The balance sheet shows negative stockholders' equity, indicating liabilities exceed assets. The debt-to-equity ratio is not calculable due to negative equity, which is concerning. This signifies financial instability and potential solvency risks.

Cash Flow

The operating and free cash flows are negative, reflecting cash burn and operational challenges. There is no positive cash generation to support operations. The cash flow situation seems unsustainable without additional financing.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00	0.00
	Gross Profit
-41.97K	-59.07K	-30.88K	-6.87K	-1.63K	-3.28K
	EBIT
-852.75K	-1.57M	-5.34M	-6.64M	-4.98M	-1.16M
	EBITDA
-1.55M	-1.60M	-5.33M	-6.63M	-4.97M	-1.15M
	Net Income Common Stockholders
-1.85M	-1.56M	-5.66M	-6.67M	-4.98M	-1.16M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
437.81K	38.60K	165.69K	1.86M	4.06M	613.57K
	Total Assets
653.55K	232.38K	442.11K	2.27M	4.69M	777.21K
	Total Debt
0.00	2.06M	2.14M	2.03M	0.00	0.00
	Net Debt
-437.81K	2.05M	1.97M	171.58K	-4.06M	-613.57K
	Total Liabilities
40.61K	4.08M	3.52M	2.64M	169.28K	69.99K
	Stockholders Equity
612.95K	-3.85M	-3.07M	-374.59K	4.52M	707.22K
Cash Flow		Free Cash Flow
-285.75K	-593.57K	-3.30M	-4.79M	-3.08M	-987.43K
	Operating Cash Flow
-285.75K	―	-3.27M	-4.76M	-3.08M	-987.43K
	Investing Cash Flow
0.00	0.00	-36.18K	-24.23K	0.00	0.00
	Financing Cash Flow
238.99K	468.18K	1.61M	2.58M	6.53M	1.29M

Izotropic Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.30
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:IZO, the sentiment is Neutral. The current price of 0.3 is below the 20-day moving average (MA) of 0.37, below the 50-day MA of 0.32, and above the 200-day MA of 0.14, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 38.30 is Neutral, neither overbought nor oversold. The STOCH value of 20.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:IZO.

Izotropic Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXE	74 Outperform	C$1.08B	14.45	70.86%	3.69%	12.36%	123.26%
NEO	71 Outperform	C$358.40M	―	-3.15%	4.66%	-15.41%	-69.47%
Sector *	48 Neutral	$6.84B	1.02	-53.11%	2.50%	16.84%	0.92%
TH	48 Neutral	$94.72M	―		―	6.07%	80.33%
PINK	48 Neutral	C$39.39M	―	-105.26%	―	56.58%	-25.14%
SVA	33 Underperform	C$49.27M	―	248.46%	―	―	32.71%
IZO	28 Underperform	C$17.04M	―	40.96%	―	―	60.83%

Izotropic Corporate Events

Izotropic Advances FDA Discussions for Breast Cancer Imaging System

Izotropic Corporation has completed a pre-submission meeting with the FDA regarding its IzoView Breast CT Imaging System, focusing on its use for breast cancer screening. The meeting facilitated a collaborative exchange, addressing key topics such as clinical study protocol, benefits versus risks of contrast-enhancement, and the management of breast cancers detected by IzoView but not visible on other imaging methods. The discussions are expected to advance the regulatory strategy for the IzoView system, potentially enhancing the company’s positioning in the breast cancer imaging market.

Izotropic to Highlight IzoView’s Market Potential at Investor Conference

Izotropic Corporation announced that its CEO, Robert Thast, will present at the Life Sciences Virtual Investor Conference, discussing the competitive advantage of their IzoView Breast CT system in the growing breast imaging market. The global breast imaging device market is projected to grow significantly, positioning Izotropic to capitalize on increased demand driven by rising breast cancer rates and regulatory changes, making this a crucial opportunity for investors to engage with the company.

Izotropic Raises $455,000 in Private Placement to Bolster Operations

Izotropic Corporation announced the completion of a non-brokered private placement financing, raising $455,000 through the issuance of 3,033,333 units at $0.15 per unit. The funds are earmarked for general and administrative purposes, and the addition of two strategic investors indicates potential future collaboration, which could impact the company’s operations and industry positioning.

Izotropic Launches Private Placement to Raise $360,000

Izotropic Corporation announced a non-brokered private placement financing to raise up to $360,000 by issuing 2,400,000 units at $0.15 each. This funding will be used for general working capital, and the offering’s completion is contingent upon regulatory approvals. The securities will not be registered under the U.S. Securities Act and won’t be available for sale in the United States.

Izotropic to Present New Regulatory Strategy at Investor Conference

Izotropic Corporation announced that its CEO, Robert Thast, will present at the Small Cap Growth Virtual Investor Conference, where he will discuss the company’s value proposition, recent achievements, regulatory approvals, and funding options. This event marks the first public presentation of Izotropic’s new regulatory strategy for U.S. FDA approval of its breast CT imaging system, IzoView, which aims to enhance breast cancer screening, particularly for patients with dense breast tissue.

Izotropic Sets Timeline for IzoView Product Launch and Expansion Plans

Izotropic has announced the timelines and milestones for the launch of its first medical imaging device, the IzoView Breast CT Imaging System, designed to improve breast cancer screening particularly for patients with dense breast tissue. The clinical study for FDA approval will be conducted across three U.S. sites, and the company plans to announce the development of two new medical imaging devices within the next year, aiming to enhance its market position and valuation.

Izotropic Gains Recognition in U.S. Breast Cancer Market Report

Izotropic has been recognized in Research and Markets’ latest report, which analyzes the U.S. breast cancer screening and diagnostic market, projected to grow from $1.55 billion in 2024 to $2.34 billion by 2030. This inclusion supports Izotropic’s regulatory strategy for its IzoView Breast CT device, suggesting a high demand for new breast imaging technologies and positioning the company for potential rapid market adoption.

Izotropic Strengthens Regulatory Team for Breast CT Imaging System

Izotropic has announced the appointment of Dr. Kyle J. Myers, Dr. Alicia Toledano, and Mr. John DeLucia as consultants to lead the clinical study design and FDA regulatory submissions for its breast CT imaging system, IzoView. This strategic move aims to expedite access to IzoView’s advanced technology, which is intended to enhance breast cancer screening for asymptomatic women with dense breast tissue. The consultants bring extensive experience from leading roles in regulatory affairs and clinical study design, which is expected to strengthen Izotropic’s positioning in the medical imaging industry and potentially improve the company’s operations and market impact.

Izotropic Seeks FDA Feedback for Breast Cancer Imaging Device

Izotropic announced the filing of a pre-submission with the U.S. FDA for the approval of its IzoView Breast CT Imaging System, designed for breast cancer screening in women with dense breast tissue. This advancement responds to a significant need for high-resolution imaging modalities that can improve early detection rates, potentially expanding the market size for IzoView scans by 800%, thus enhancing Izotropic’s market positioning and addressing critical healthcare demands.